Abstract
Recently, enfortumab vedotin has emerged as a promising treatment option for metastatic urothelial carcinoma. Although it does not require dosage adjustments in patients with renal failure, its safety and efficacy, particularly in those undergoing dialysis, remain unclear. We report a case of metastatic urothelial carcinoma in a patient undergoing hemodialysis who achieved a complete response to enfortumab vedotin therapy without severe adverse events. This complete response was maintained for two years without any severe complications. Our case demonstrates that enfortumab vedotin can be safely administered long-term to patients undergoing hemodialysis.